16 stories mentioning WST
Every FINWIRES story that references WST, newest first.
West Pharmaceutical Services (WST) has an average rating of buy and mean price target of $362.54, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding about 0.7%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, West Pharmaceutical Services (WST) shares rose 3.1% after the company said it has restored its core enterprise systems following a recent cybersecurity attack.Eli Lilly (LLY) shares added 2.6% after the company said its investigational retatrutide delivered "clinically meaningful" weight loss in a phase 3 trial, where all doses met the primary and key secondary endpoints at 80 weeks.Hims & Hers Health (HIMS) said Thursday that it has launched generic semaglutide for eligible customers in Canada. Its shares gained 2.7%.Moderna's (MRNA) experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory panel on June 18, Bloomberg reported. Moderna shares were down 1.5%.
Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 0.7%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, West Pharmaceutical Services (WST) shares rose 2.7% after the company said it has restored its core enterprise systems following a recent cybersecurity attack.
West Pharmaceutical Services (WST) shares rose 3% on Thursday after the company said it has restored its core enterprise systems following a recent cybersecurity attack.The company is now fully operational across its manufacturing, supply chain and commercial sites globally, it said in a regulatory filing late Wednesday.While the investigation into the nature and scope of the incident is ongoing, including with respect to the extent of data affected, no unauthorized activity or access has been observed since May 5, the company added.West Pharmaceutical said the incident has not had a material impact on its Q2 and full-year 2026 financial guidance.Price: $314.34, Change: $+8.83, Percent Change: +2.89%
Healthcare stocks advanced late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each rising about 2%.The iShares Biotechnology ETF (IBB) increased 1.2%.In sector news, President Donald Trump said Tuesday that US Food and Drug Administration Commissioner Marty Makary is resigning, Bloomberg reported.In corporate news, West Pharmaceutical Services (WST) shares were down 3% after the company said in a regulatory filing its global operations were disrupted by a cyberattack.Alkermes (ALKS) shares jumped past 7% after the firm said Tuesday a late-stage trial of Lumryz oral suspension in adults with idiopathic hypersomnia, a rare condition in which patients require excessive sleep, met all primary and secondary targets.Sonida Senior Living's (SNDA) recent stock decline was unwarranted given the broad-based strength in its Q1 results, RBC said in a note. RBC kept its outperform rating and raised its price target to $45 from $39. Shares eased 0.2%.Dr. Reddy's Laboratories (RDY) plans to launch a generic version of Novo Nordisk's (NVO) Ozempic this month in Canada, Bloomberg reported Tuesday, citing Chief Executive Erez Israeli. Dr. Reddy's shares fell 5.3%, and Novo rose 1.1%.
Healthcare stocks advanced late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each rising 2%.The iShares Biotechnology ETF (IBB) increased 1.2%.In sector news, President Donald Trump said Tuesday that US Food and Drug Administration Commissioner Marty Makary is resigning, Bloomberg reported.In corporate news, West Pharmaceutical Services (WST) shares were down 2.3% after the company said in a regulatory filing its global operations were disrupted by a cyberattack.
West Pharmaceutical Services (WST) shares were down more than 2% in intraday trading on Tuesday after the company said its global operations were disrupted by a cyberattack, according to a regulatory filing.The company said it detected an intrusion on May 4, in which certain data was exfiltrated by an unauthorized party and some systems were encrypted.West Pharmaceutical said it activated its incident response protocols, including taking systems offline globally for containment, notifying law enforcement and engaging external cyber-forensic experts.The company said its investigation is ongoing and the timeline for full restoration of operations has not yet been determined.Price: $315.43, Change: $-6.87, Percent Change: -2.13%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price is $390, raised from $350. This is 45.2x our 2026 EPS estimate (up $0.09 to $8.62; 2027 estimate up $0.13 to $9.55), above WST's five- and 10-year forward averages of 41.9x and 42.2x, respectively. Our valuation reflects the strength of the HVP business, with capital expansion plans for additional HVP capacity, as well as a growing market for GLP-1 elastomer sales and significant balance sheet health (negative net debt). WST leads all S&P Composite 1500 Life Sciences Tools and Sevices firms in YTD performance (+18% through May 8) despite significant pressure on the sub-industry (-17%). We think WST remains well positioned to benefit from GLP-1 demand as well as non-GLP-1 biologics growth, offering less exposure to cyclicality in academia/government R&D budgets and adverse China policies that we think are pressuring peers. We see near-term sales, margin, and earnings growth supporting WST's valuation, with negative net debt supporting financial flexibility and lowering downside risk.
Annette F Favorite, Senior Vice President & Chief Human Resources Officer, on April 27, 2026, sold 2,817 shares in West Pharmaceutical Services (WST) for $859,753. Following the Form 4 filing with the SEC, Favorite has control over a total of 21,795 common shares of the company, with 16,828 shares held directly and 4,967 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/105770/000010577026000054/xslF345X05/form4.xmlPrice: $294.39, Change: $+2.47, Percent Change: +0.85%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price is $350, up from $267 and represents 41x our 2026 EPS estimate (up $0.63 to $8.53; 2027's up $0.61 to $9.42), near WST's five-year forward average of 42x. Our valuation reflects our view of the strength of the High-Value Products (HVP) business, as well as a growing market for GLP-1 elastomer sales and significant balance sheet health (negative net debt). We anticipate new drug development will support the HVP business, as biologics made up around 42% of sales during Q1 2026. Further, GLP-1 drug demand may provide a new catalyst for sales of syringes. WST secured a multiyear contract with Novo Nordisk for all its GLP-1 primary packaging elastomer needs, and GLP-1 elastomers comprised 10% of Q1 2026 sales. Combined with sales in the West Vantage segment, GLP-1 exposure made up 18% of total net sales during the quarter. The Annex 1 regulatory updates for medical manufacturing also provide tailwinds for HVP via quality upgrade projects for existing WST components, in our view.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price is $350, up from $267 and represents 41x our 2026 EPS estimate (up $0.63 to $8.53; 2027's up $0.61 to $9.42), near WST's five-year forward average of 42x. Our valuation reflects our view of the strength of the High-Value Products (HVP) business, as well as a growing market for GLP-1 elastomer sales and significant balance sheet health (negative net debt). We anticipate new drug development will support the HVP business, as biologics made up around 42% of sales during Q1 2026. Further, GLP-1 drug demand may provide a new catalyst for sales of syringes. WST secured a multiyear contract with Novo Nordisk for all its GLP-1 primary packaging elastomer needs, which comprised 10% of Q1 2026 sales. Combined with sales in the West Vantage segment, GLP-1 exposure made up 18% of total net sales during the quarter. The Annex 1 regulatory updates for medical manufacturing also provide tailwinds for HVP via quality upgrade projects for existing WST components, in our view.
West Pharmaceutical Services (WST) has an average rating of overweight and mean price target of $345.69, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $302.99, Change: $-6.71, Percent Change: -2.17%
Texas Instruments (TXN) reported higher Q1 earnings and revenue late Wednesday and also set out Q2 guidance above consensus.Shares advanced 19% as intraday trading volume soared to over 17 million from a daily average of roughly 7.4 million.United Rentals (URI) reported overnight higher Q1 adjusted earnings and revenue and lifted its 2026 sales guidance.Shares soared 21%, with intraday trading volume climbing over 925,500 from a daily average of about 656,000.West Pharmaceutical Services (WST) reported higher Q1 non-GAAP earnings and net sales on Thursday. The company also issued a Q2 outlook above analysts' expectations and raised its 2026 guidance.Shares climbed 12% as intraday trading volume jumped to over 1.47 million from a daily average of about 944,000.Price: $281.28, Change: $+44.97, Percent Change: +19.03%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:West delivered Q1 EPS of $2.13 (+46.9% Y/Y) vs. the $1.68 consensus and net sales of $844.9M (+21.0% Y/Y) vs. the $779.4M consensus, significantly exceeding expectations. HVP Components revenue reached $409.3M (+29.6% Y/Y), now comprising 48% of total sales, while GLP-1 exposure expanded to 18% of net sales. Gross margin improved 190 bps to 35.1% while adjusted operating margin rose 350 bps to 21.4%, supported by favorable product mix toward HVP components. Strength in Westar and NovaPure products, combined with double-digit non-GLP-1 organic growth, indicates broad-based demand recovery beyond diabetes/obesity treatments, in our view. Given strong Q1 performance, WST raised 2026 guidance significantly with net sales to $3.295B-$3.350B and adjusted EPS to $8.40-$8.75, representing 15.2%-20.0% growth.
Health care stocks were declining premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3% and the iShares Biotechnology ETF (IBB) 0.7% lower.Thermo Fisher Scientific (TMO) stock was down more than 9% even after the company posted higher fiscal Q1 adjusted earnings and revenue.Sanofi (SNY) shares were up more than 3% after the company reported higher Q1 adjusted earnings and net sales.West Pharmaceutical Services (WST) stock was up more than 16% after the company reported higher Q1 non-GAAP earnings and net sales. West Pharmaceutical Services also issued Q2 outlook above analysts' expectations and raised its 2026 guidance.
West Pharmaceutical Services (WST) reported Q1 non-GAAP earnings Thursday of $2.13 per diluted share, up from $1.45 a year earlier.Analysts polled by FactSet expected $1.68.Net sales for the quarter ended March 31 were $844.9 million, compared with $698 million a year earlier.Analysts surveyed by FactSet expected $780.3 million.The company expects Q2 adjusted EPS of $2.05 to $2.12. Analysts surveyed by FactSet expect $2.Revenue for the quarter is projected to be between $830 million and $850 million. Analysts polled by FactSet expect $818.4 million.For 2026, the company now expects 2026 adjusted EPS of $8.40 to $8.75, compared with its prior guidance of $7.85 to $8.20. Analysts polled by FactSet expect $8.01.Revenue for the full-year is now projected to be about $3.30 billion to $3.35 billion, compared with its earlier outlook of $3.22 billion to $3.28 billion. Analysts polled by FactSet expect $3.25 billion.Shares of the company were over 10% higher in Thursday premarket activity.Price: $310.00, Change: $+35.59, Percent Change: +12.97%